DisGeNET - a database of gene-disease associations

Colorectal Neoplasms, C0009404

Gene: PIK3CA ×

Source: CLINVAR ×

Results per page

Gene

Disease

Variant

Source

Association Type

Semantic type

Protein Class

Disease Class

Type

Original DB

Consequence

DSI _v

DPI _v

pLI

EI _vda

EL _gda

Score _vda

PMID

PMID Year

AF_EXOME

Num. PMIDs

Num. SNPs_gda

AF_GENOME

Variant

Gene

Risk Allele

Score _vda

Association Type

Original DB

Sentence supporting the association

PMID

PMID Year

dbSNP:

rs104886003

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs104886003

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs1057519699

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs121913273

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs121913274

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs121913274

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs121913274

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs121913279

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs121913279

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs121913286

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs121913286

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs397517201

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs397517201

PIK3CA

0.700

CausalMutation

CLINVAR

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

18725974

2008

dbSNP:

rs104886003

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs104886003

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs1057519699

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs121913273

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs121913274

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs121913274

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs121913274

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs121913279

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs121913279

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs121913286

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs121913286

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010

dbSNP:

rs397517201

PIK3CA

0.700

CausalMutation

CLINVAR

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

20619739

2010